Immunitor Presents V5 Trial Data and Receives Award at TB Conference in Hong Kong
09 Julho 2011 - 7:57AM
Immune Network Ltd. (Pink Sheets:IMMFF) advises that Immunitor's
investigators presented final results from its imm01 clinical trial
and received the Scientific Award as one of the best presentations
at the 3rd Asia Pacific Region Conference of the International
Union Against Tuberculosis and Lung Disease being held at Hong Kong
Convention Center on July 8-11, 2011
(http://www.2011apr-unionc.org.hk ).
The Immunitor presentation summarized data from imm01 phase IIb
trial in Ukraine. Preliminary interim results were published in two
peer-reviewed journals earlier this year
(http://www.ncbi.nlm.nih.gov/pubmed/21182457 and
http://www.ncbi.nlm.nih.gov/pubmed/21244690 ). The study, conducted
by internationally recognized experts in TB immunotherapy, aimed to
compare V5 immunotherapy to placebo among treatment refractory
tuberculosis cases including re-treated TB, multi-drug resistant
(MDR-TB) and TB with HIV co-infection. After one month, 55 out of
61 patients (90.2%) in V5 group had undetectable TB bacteria in
their sputum, whereas only 9/61 (14.8%) in placebo group had
negative conversion. The high conversion rate in V5-receiving
subjects was similar, regardless whether TB was drug-sensitive or
drug-resistant (MDR-TB), or together with HIV. Even patients who
failed all available treatment options responded favorably when V5
was added to the TB drug regimen. These results suggest that
addition of V5 may produce 5-fold higher cure rate than standard
treatment alone.
V5 down-regulated TB-associated inflammation as shown by
normalization of mean elevated leukocyte counts, decreased
erythrocyte sedimentation rate, and normalization of fever.
Immunotherapy was also associated with improvement in weight gain –
patients on V5 re-gained about three-fold more weight than
controls. No adverse side effects or reactivation of TB
attributable to V5 were seen at any time. Quite the opposite, V5
appeared to effectively combat side effects of TB drugs as
evidenced by reversal of drug-induced liver dysfunction. The
completed study confirmed earlier observations that V5 was safe and
effective as an immune adjunct to chemotherapeutic management of TB
and can potentially shorten the duration of treatment down to one
month, even for MDR-TB. These results have attracted considerable
attention in countries with high TB burden. Negotiations are now
underway in Philippines, India, South Africa and Russia to confirm
these findings.
After AIDS, tuberculosis is the second most common cause of
death from an infectious disease, with approximately 2 million
people dying each year. Current treatments are not fully effective,
particularly against MDR-TB and HIV-TB and strenuous treatment
regimens lasting for up to 2 years are required.
"Receiving the award at the conference is a great honor to us
and especially to our clinical investigators in Ukraine, who
conducted this milestone study. V5 is inexpensive, easy to
administer, stable at tropical temperatures, and is made from
readily available source, which suits ideally developing
countries," said Vichai Jirathitikal, co-founder and co-inventor of
Immunitor oral vaccine platform. For additional information about
Immunitor company, please visit www.immunitor.com.
Immune Network website is http://www.immune-network.com.
Immune Network logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8008.
Safe Harbor Statement
The information in this release, other than historical
information, may be considered forward-looking statements within
the provisions of the Private Securities Litigation Reform Act of
1995. Projection and other forward-looking statements and
management expectations regarding future events and/or financial
performance of the Company -- although given in good faith -- are
inherently uncertain and actual events and/or results may differ
materially.
CONTACT: Immune Network Ltd
IMMFF@yahoo.com
Omni Bridgeway (PK) (USOTC:IMMFF)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Omni Bridgeway (PK) (USOTC:IMMFF)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024